Joint Guidance on Virtual and Hybrid International Medical Congresses

Joint Guidance on Virtual and Hybrid International Medical Congresses

May 2022
Authors: Irene Kyriakides, Victoria Mertikopoulou, KG Law Firm

Very recently, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the Pharmaceutical Research and Manufacturers of America (PhRMA) published a Joint Guidance on Virtual and Hybrid International Medical Congresses, aiming to specify the parameters and factors that Companies should consider when determining which code and/or label to use as a reference for the Company activities. 

The Joint Guidance clarifies, among others, that:

  • Companies should use IFPMA Code as the minimum standard. EFPIA and PhRMA Codes mirror the principles and rules of the IFPMA Code. They should be examined in connection with the latter when a European or American medical association hosts scientific events/meetings/congresses.
  • Companies should consider the region’s code from which the majority of delegates are expected to come based on past experience. In case there is no regional code, the IFPMA code shall apply.

  • As regards Hybrid Congresses, the code of the in-person location country should apply. Symposia streamed into a hub should comply with the requirements of the jurisdiction of the primary location for the meeting.

  • Companies should have a process to confirm participants’ status as HCPs/Non-HCPs.
  • Congress attendees participating virtually should sign a digital consent form indicating awareness/acknowledging virtual and hybrid congress terms and conditions.
  • Congress materials should be directly accessible from the Congress Platform.
  • Companies should include a statement addressed to delegates when entering their virtual booth/exhibition, clarifying the context under which the materials have been developed and noting that the content may not be applicable to their country.

For clarifications and assistance in interpreting the Joint Guidance please refer to the IFPMA/EFPIA/PhRMA Joint Guidance on Virtual and Hybrid International Medical Congresses: Questions & Answers (Q&A) Introduction.

May 2022
Authors: Irene Kyriakides, Victoria Mertikopoulou, KG Law Firm

Very recently, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the Pharmaceutical Research and Manufacturers of America (PhRMA) published a Joint Guidance on Virtual and Hybrid International Medical Congresses, aiming to specify the parameters and factors that Companies should consider when determining which code and/or label to use as a reference for the Company activities. 

The Joint Guidance clarifies, among others, that:

  • Companies should use IFPMA Code as the minimum standard. EFPIA and PhRMA Codes mirror the principles and rules of the IFPMA Code. They should be examined in connection with the latter when a European or American medical association hosts scientific events/meetings/congresses.
  • Companies should consider the region’s code from which the majority of delegates are expected to come based on past experience. In case there is no regional code, the IFPMA code shall apply.

  • As regards Hybrid Congresses, the code of the in-person location country should apply. Symposia streamed into a hub should comply with the requirements of the jurisdiction of the primary location for the meeting.

  • Companies should have a process to confirm participants’ status as HCPs/Non-HCPs.
  • Congress attendees participating virtually should sign a digital consent form indicating awareness/acknowledging virtual and hybrid congress terms and conditions.
  • Congress materials should be directly accessible from the Congress Platform.
  • Companies should include a statement addressed to delegates when entering their virtual booth/exhibition, clarifying the context under which the materials have been developed and noting that the content may not be applicable to their country.

For clarifications and assistance in interpreting the Joint Guidance please refer to the IFPMA/EFPIA/PhRMA Joint Guidance on Virtual and Hybrid International Medical Congresses: Questions & Answers (Q&A) Introduction.